IL1 Cancer Research Results

IL1, Interleukin-1: Click to Expand ⟱
Source:
Type:
Interleukin-1 (IL-1) has long been known to be a key mediator of immunity and inflammation. Its dysregulation has been implicated in recent years in tumorigenesis and tumor progression, and its upregulation is thought to be associated with many tumors.

Interleukin-1 (IL-1) is a pro-inflammatory cytokine that plays a crucial role in the immune response and inflammation. It exists in two main forms: IL-1α and IL-1β, both of which are produced by various cell types, including macrophages, monocytes, and dendritic cells. IL-1 is involved in a wide range of biological processes, including cell proliferation, differentiation, and apoptosis.

IL-1 is often overexpressed in various cancers, including breast cancer, colorectal cancer, lung cancer, and melanoma. Its expression can be influenced by the tumor microenvironment and the presence of inflammatory cells.
Elevated levels of IL-1 are frequently associated with tumor progression and metastasis.

IL-1 is considered a pro-tumorigenic cytokine in many contexts. It can promote tumor growth by enhancing cell proliferation, survival, and angiogenesis. IL-1β, in particular, has been shown to stimulate the proliferation of cancer cells and promote the formation of new blood vessels (angiogenesis).
Pca, Prostate Cancer: Click to Expand ⟱
Prostate Cancer: Alterations in genes such as ERG, SPOP, MYC, androgen receptor (AR), and CHD1, drive PCa progression.
TP53 is the most commonly mutated gene in human cancer.
HH↑, GLI-1↑, SHH↑ P53↓
The loss of p53 and/or other tumor suppressor genes, reduced capacity for DNA repair, the dysfunction of telomerase activity, and changes in the pathways that govern the growth of cells also mediate the progression of Pca.
It has been well documented that Ca2+ influx and MDR1 upregulation are highly associated with GEM metabolism in human pancreatic carcinoma.
Increased Growth factor IGF-1/IGF-1R axis activation mediated by both PI3K/Akt or RAF/MEK/ERK system and AR expression remains important in the development and progression of prostate cancer.
It has been demonstrated that prostate cancer cells are relatively sensitive to heat stress.
Long non-coding RNA MALAT1 has been reported as an oncogenic target in multiple types of cancers, including PC.
Scientific Papers found: Click to Expand⟱
4780- Lyco,    Potential inhibitory effect of lycopene on prostate cancer
- Review, Pca, NA
TumCP↓, TumCCA↑, Apoptosis↑, *neuroP↑, *NF-kB↓, *JNK↓, *NRF2↑, *BDNF↑, *Ca+2↝, *antiOx↑, *AntiCan↑, *Inflam↓, *IL1↓, *IL6↓, *IL8↓, *TNF-α↓, NF-kB↓, DNAdam↓, PSA↓, P53↓, cycD1/CCND1↓, NRF2↓, Akt2↓, PPARγ↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

NRF2↓, 1,  

Core Metabolism/Glycolysis ⓘ

PPARγ↓, 1,  

Cell Death ⓘ

Apoptosis↑, 1,  

DNA Damage & Repair ⓘ

DNAdam↓, 1,   P53↓, 1,  

Cell Cycle & Senescence ⓘ

cycD1/CCND1↓, 1,   TumCCA↑, 1,  

Migration ⓘ

Akt2↓, 1,   TumCP↓, 1,  

Immune & Inflammatory Signaling ⓘ

NF-kB↓, 1,   PSA↓, 1,  

Clinical Biomarkers ⓘ

PSA↓, 1,  
Total Targets: 12

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,   NRF2↑, 1,  

Cell Death ⓘ

JNK↓, 1,  

Migration ⓘ

Ca+2↝, 1,  

Immune & Inflammatory Signaling ⓘ

IL1↓, 1,   IL6↓, 1,   IL8↓, 1,   Inflam↓, 1,   NF-kB↓, 1,   TNF-α↓, 1,  

Synaptic & Neurotransmission ⓘ

BDNF↑, 1,  

Clinical Biomarkers ⓘ

IL6↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 1,   neuroP↑, 1,  
Total Targets: 14

Scientific Paper Hit Count for: IL1, Interleukin-1
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:22  Cells:%  prod#:%  Target#:365  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page